

**Recommendations of the
Informal Consultation on Issues for
Clinical Product Development for
Human African Trypanosomiasis**

**Geneva, Switzerland
9–10 September 2004**



**World Health
Organization**

© World Health Organization 2007

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Printed by the WHO Document Production Services, Geneva, Switzerland

**Recommendations of the
Informal Consultation on Issues for
Clinical Product Development for
Human African Trypanosomiasis**

**Geneva, Switzerland
9–10 September 2004**



© World Health Organization 2007

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Printed by the WHO Document Production Services, Geneva, Switzerland

**Recommendations of the
Informal Consultation on Issues for
Clinical Product Development for
Human African Trypanosomiasis**

**Geneva, Switzerland
9–10 September 2004**



Table of contents

1	Introduction	1
2	Identification of patients for clinical trials.....	2
2.1	Diagnosis.....	2
2.2	Staging	2
2.3	Methodological considerations	3
2.3.1	Diagnosis of patients to be included in clinical trials	3
2.3.2	Examination of CSF for staging	3
2.3.3	Evaluation of patients at end-of-treatment and at post-treatment follow-up.....	4
2.4	Collaboration between clinical trial teams and national control programmes for identification of patients for clinical trials	5
3	Evaluation of new surrogate markers	6
4	Time-point for final assessment of efficacy (ToC visit).....	6
5	Patient evaluation and criteria for assessment of efficacy.....	8
5.1	Patients with first-stage HAT.....	10
5.1.1	Evaluation of first-stage patients at the end of treatment	10
5.1.2	Evaluation of first-stage patients during interim follow-up.....	11
5.1.3	Test-of-cure evaluation for first-stage patients	11
5.1.4	Deaths	14
5.2	Patients with second-stage HAT	14
5.2.1	Evaluation of second-stage patients at EoT	14
5.2.2	Evaluation of second-stage patients during interim follow-up	15
5.2.3	ToC evaluation of second-stage patients	15
5.2.4	Deaths	17
6	Quantification of efficacy	17
6.1	Analysis populations	17
6.2	Time windows for assigning patient follow-up data to times after treatment, for efficacy analysis	21
6.3	Handling of missing efficacy data	23
6.4	Efficacy variables.....	25
6.4.1	Nomenclature	25
6.4.2	Calculation of efficacy	26
7	List of participants	28

Appendix.....	33
Briefing document for the Informal Consultation on Clinical Trials for Trypanosomiasis	33
1. Introduction	35
2. Diagnostic criteria	35
2.1 Criteria for diagnosis of first- and second-stage African trypanosomiasis caused by <i>T. b. gambiense</i>	35
2.1.1 Diagnosis.....	35
2.1.2 Staging	36
2.2 Criteria for diagnosing relapse.....	38
2.2.1 Diagnosis of relapse in first-stage HAT.....	38
2.2.2 Diagnosis of relapse (or re-infection) in second-stage HAT	39
2.2.3 Diagnosis of 'suspected relapse'	40
2.2.4 Diagnosis of cure	40
2.3 Methodological issues.....	41
2.3.1 Serological assessment.....	41
2.3.2 Parasite detection	41
2.4 Potential surrogate markers for cure/relapse.....	44
2.4.1 Currently available data on surrogate end-points	44
2.4.2 Validation of surrogate end-points.....	46
2.5 Patient evaluation for relapse/cure in clinical trials	46
3. HAT-specific challenges for the clinical evaluation of a new treatment modality	48
3.1 Requirements for build-up of clinical trial sites.....	49
3.2 Identification of patients for clinical trials of new treatment modalities	49
3.3 Time of relapse in recent disease control treatment programmes and clinical studies.....	51

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29568

